Brandon Scalea

Articles

Landgren Explains Crucial Role of MRD in Myeloma

December 13th 2018

C. Ola Landgren, MD, PhD, discusses the role of minimal residual disease negativity and the emergence of CAR T-cell therapy in multiple myeloma.

PACIFIC Trial Changes Standard of Care in Stage III NSCLC

December 12th 2018

Adham Jurdi, MD, discusses how the updated data from the PACIFIC trial have changed the standard of care for patients with stage III non–small cell lung cancer.

Denosumab Safe, Effective in Increasing Bone Density in Nonmetastatic Prostate Cancer

December 11th 2018

Scott T. Tagawa, MD, MS, discusses the clinical significance of recent clinical trial data in patients with nonmetastatic prostate cancer.

Expert Highlights TAS-102 Potential in Gastric/GEJ Cancer

December 11th 2018

Although gastric and gastroesophageal junction cancers are heterogeneous diseases with a number of FDA-approved regimens, TAS-102 may have a place in the management of previously treated patients, according to Hendrik-Tobias Arkenau, MD, PhD.

Experts Highlight Developments in Lung, GI Cancers

December 11th 2018

Recent data have moved the needle across the board in oncology, specifically with lung cancer and gastrointestinal cancers, with immunotherapy and targeted agents paving the way for an improvement in survival outcomes.

GI Cancer Treatment Continues to Evolve, But Unmet Needs Remain

December 1st 2018

Cathy Eng, MD, shares her insight on the current paradigm of gastrointestinal cancers, specifically colorectal cancer and hepatocellular carcinoma.

Brahmer Shares Next Steps for Immunotherapy in Metastatic NSCLC

December 1st 2018

Julie R. Brahmer, MD, discusses updates on the use of immunotherapy in patients with metastatic non–small cell lung cancer.

Expert Highlights Management of Immune-Related Toxicities With NSCLC Treatment

November 29th 2018

Pembrolizumab has emerged as a reliable frontline treatment option for patients with metastatic non–small cell lung cancer, but thoracic oncologists need to be aware of potentially severe immune-related adverse events.

Treatments Emerging for ROS1-, BRAF-Driven Lung Cancers

November 28th 2018

Deepa S. Subramaniam, MBBS, MSc, discusses the complex and evolving treatment paradigm of BRAF- and ROS1-driven non–small cell lung cancer.

O'Regan Highlights CDK4/6 Agents, Other Developments in ER+ Breast Cancer

November 27th 2018

Ruth O’Regan, MD, discusses the current landscape of hormone receptor–positive breast cancer and the unanswered questions that still need to be addressed.

Cemiplimab Shows Potential in Cervical Cancer

November 27th 2018

Danny Rischin, MD, discusses the potential of cemiplimab in patients with cervical cancer.

Lead Researcher Discusses Alpelisib in PIK3CA+ Breast Cancer

November 26th 2018

Fabrice Andre, MD, PhD, discusses the SOLAR-1 findings and their impact on the breast cancer landscape.

Dose-Escalation Strategy Feasible With Novel Radionuclide Treatment in mCRPC

November 21st 2018

Scott T. Tagawa, MD, discusses an emerging treatment modality for patients with progressive metastatic castration-resistant prostate cancer.

Cohen Discusses Future of MCL Treatment

November 20th 2018

Jonathon B. Cohen, MD, discusses the evolving landscape of mantle cell lymphoma.

Choueiri Highlights Promising Avelumab/Axitinib Data in RCC

November 20th 2018

Toni K. Choueiri, MD, discusses the JAVELIN Renal 101 study and where these data fit into the complex treatment paradigm of renal cell carcinoma.

Pegram Discusses Future of Biosimilars in Oncology

November 19th 2018

Mark D. Pegram, MD, highlights the gradually evolving landscape of biosimilars and provides insight on how they can shape the US market.

Thoracic Oncologist Highlights Recent Pembrolizumab Data in NSCLC

November 19th 2018

Pembrolizumab (Keytruda) has emerged as an effective frontline treatment option for select patients with metastatic non–small cell lung cancer, showing an overall survival advantage across 3 phase III clinical trials.

Dabrafenib Plus Trametinib Demonstrates Activity in GI Cancers

November 17th 2018

The combination of dabrafenib and trametinib led to encouraging responses in patients with rare, incurable cancer of the digestive tract.

Expert Explains Treatment Approaches for MCL

November 15th 2018

Simon Rule, MD, PhD, discusses the observational and active therapeutic approaches for patients with mantle cell lymphoma.

Expert Explains Surgical Considerations in High-Risk Prostate Cancer

November 13th 2018

James Kearns, MD, discusses key issues to consider with surgery in patients with high-risk prostate cancer.